Serum lipid levels associated with increased risk for cardiovascular disease is associated with highly active antiretroviral therapy (HAART) in HIV-1 infection

International Journal of STD and AIDS

Volumn 11, Issue 7, 2000, Pages 451-455

  Koppel, Kristina ^a   Bratt, Göran ^a   Eriksson, Mats ^b   Sandström, Eric ^a  

^a STOCKHOLM SÖDER HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Highly active antiretroviral therapy (HAART); HIV 1; Hyperlipidaemia; Lipodystrophy; Lipoprotein(a)

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEINASE INHIBITOR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0034093959     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462001916236     Document Type: Article

References (28)

1. 1 Mocroft A, Vella S, Benfield T, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet 1999;352:1725-30
2. 2 Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 1997;277:1962-9
3. 3 Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995;333: 1528-33
4. 4 Miller K, Joes E, Yanovski J, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998;351:871-5
5. 5 Shaw A, McLean K, Evans B. Disorders of fat distribution in HIV infection. Int J STD AIDS 1998;9:595-9
6. 6 Carr A, Samaras K, Thorisdottir A, Kaufmann G, Chrisholm D, Cooper D. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidemia, and diabetes mellitus: a cohort study. Lancet 1999;353:2093-105
7. 7 Hengel R, Watts N, Lennox J. Benign symmetric lipomatosis associated with protease inhibitors. Lancet 1997;350:1596
8. 8 Lo J, Mulligan K, Tai V, Algren H, Schambelan M. 'Buffalo hump' in men with HIV-1 infection. Lancet 1998;351:867-70
9. 9 Viraben R, Aquilina C. Indinavir-associated lipodystrophy. AIDS 1998;12:F37-9
10. 10 Saint-Marc T, Touraine J. Truncal adiposity syndrome, hyperinsulinemia, endocrine and metabolic disorders in patients receiving HIV protease inhibitors (Abstract 152). 4th International Congress on Drug Therapy in HIV Infection. AIDS 1998; suppl 4
11. 11 Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998;12:F167-73
12. 12 Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8
13. 13 Périard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. Circulation 1999;100:700-5
14. 14 Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998;351:1881-3
15. 15 Brinkman K, Smeitink J, Romijn J, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999; 354:1112-15
16. 16 Henry K, Melroe H, Huebsch J, et al. Severe premature coronary artery disease with protease inhibitors. Lancet 1998;351:1328
17. 17 Karmochkine M, Raguin G. Severe coronary disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir. AIDS 1998;12:2499
18. 18 Koppel K, Bratt G, Rajs J. Sudden cardiac death in a patient on 2 years highly active antiretroviral treatment (HAART) - a case report. AIDS 1999;13:1993-4
19. 19 Maher V, Brown B. Lipoprotein(a) and coronary heart disease. Curr Opin Lipidol 1995;6:229-35
20. 20 Maher V, Brown B, Marcovina S, Hillger L, Zhao X, Albers J. Effects of lowering elevated LDL cholesterol on the cardiovascular risk of lipoprotein(a). JAMA 1995;274:1771-4
21. 21 Dahlén G, Stenlund H. Lp(a) lipoprotein is a major risk factor for cardiovascular disease: pathogenic mechanisms and clinical significance. Clin Genet 1997;52:272-80
22. 22 Dahlén G, Weinehall L, Stenlund H, et al. Lipoprotein(a) and cholesterol levels act synergistically and apolipoprotein A-I is protective for the incidence of primary acute myocardial infarction in middle-aged males. An incident case-control study from Sweden. J Intern Med 1998;244:425-30
23. 23 Dahlén G, Srinivasan S, Stenlund H, Wattigney W, Wall S, Berenson G. The importance of serum lipoprotein(a) as an independent risk factor for premature coronary artery disease in middle-aged black and white women from the United States. J Intern Med 1998;244:417-24
24. 24 Albers J. The measurement of Lp(a) and its clinical application. In: Scanu A, ed. Lipoprotein(a). San Diego: Academic Press, 1990:141-9
25. 25 Berg K, Dahlén G, Christophersen B, Cook T, Kjekshus J, Pedersen T. Lp(a) lipoprotein levels predict survival and major coronary events in the Scandinavian Simvastatin Survival Study. Clin Genet 1997;52:254-61
26. 26 Averna M, Barbagallo C, Ocello S, et al. Lp(a) levels in patients undergoing aorto-coronary bypass surgery. Eur Heart J 1992;13:1405-9
27. 27 Constans J, Wendling G, Peuchant E, Camilleri G, Conri C. Lipoprotein(a) in 505 hospitalized patients with various pathological states: correlation with cardiovascular diseases and therapies. Int Angiol 1996;15:1-5
28. 28 Dahlén G. Incidence of Lp(a) lipoprotein among populations. In: Scanu A, ed. Lipoprotein(a) San Diego: Academic Press, 1990:151-73